Still hungry after your first dose of Mounjaro? That's expected

The biggest misconception: 2.5mg should switch off your appetite

Many people arrive at their first injection expecting a dramatic shift in hunger within days. The misconception is understandable. Media coverage of Mounjaro tends to lead with its headline trial results, and those figures (roughly 20% average body-weight reduction in the SURMOUNT-1 trial published in the New England Journal of Medicine) are striking. What the headlines rarely explain is that those results came at the highest maintenance doses, after many months of titration, not after a single 2.5mg injection.

Tirzepatide works by activating both GLP-1 and GIP receptors, which slows gastric emptying and gradually shifts the body's satiety signals. That shift takes time. The 2.5mg starting dose is titrated upward roughly every four weeks by your prescriber, and appetite suppression tends to become more noticeable from 5mg onward. Some people feel subtle changes in the first two weeks; many do not. Both are within normal range.

If you are still hungry on your 2.5mg pen, you have not been given a faulty product and you have not been assessed incorrectly. You are simply at the beginning of a dose schedule designed for safety first. Our page covering hunger on 2.5mg specifically goes into the pharmacology in more detail if you want the fuller picture.

What actually drives appetite change on Mounjaro, and when to expect it

Tirzepatide slows the rate at which food leaves your stomach. Food sits longer, stretch receptors in the stomach wall stay activated for longer, and the brain receives satiety signals earlier and more persistently. At the same time, GLP-1 receptor activation influences appetite-regulating centres in the hypothalamus. The GIP component may amplify this. None of these mechanisms switch on fully at the starting dose.

A practical habit worth building in your first week: note the time you last felt genuinely full after a meal, and compare it with the same meal a fortnight later. Even before any dramatic change in hunger, many people find fullness arrives a few minutes sooner. That shift is the first sign the medicine is doing something. It is not always the dramatic appetite drop described in press articles.

As your dose increases, the effect typically strengthens. The 5mg dose is where many patients report their first clear reduction in hunger. By the time prescribers reach higher doses such as 12.5mg or 15mg, appetite suppression is usually more pronounced, though individual response varies and the right dose for you is always a clinical decision, not a target to rush toward.

What to do if hunger feels unchanged after several weeks

If you have completed your first pen and hunger remains completely unchanged, two things are worth considering. First, confirm the injection technique. Tirzepatide is subcutaneous (injected into the fatty tissue of the abdomen, thigh, or upper arm) and delivery into muscle rather than fat can affect absorption. The NHS medicines page for tirzepatide covers technique and what the Patient Information Leaflet says about injection sites; it is worth reading before your next dose.

Second, contact your prescriber. If you are several weeks in and there is genuinely no effect on hunger, fullness, or food noise, that is clinically relevant information. A prescriber can review your response, consider whether the titration schedule suits you, and check that nothing else is interfering, certain other medicines, for example, can blunt the effect. At nume, a real clinician reads every update; our aftercare team is available seven days a week for exactly this kind of question.

It is also worth being honest with yourself about what "hungry" means in this context. Some people on GLP-1 treatment find physical hunger reduces but habitual eating urges (eating from boredom or routine rather than hunger) persist. Those are different mechanisms and may need different strategies alongside the medication. Our FAQs address this distinction, and your prescriber can help you tease it apart.

Cost, oversight, and the value of staying in clinical contact

One question that surfaces after a first dose with no obvious effect is whether to try a different provider or a higher dose sooner. On cost: the Eli Lilly price increase in September 2025 raised private market prices considerably, so it is understandable that people want to feel results quickly. That pressure can push patients toward changing provider or skipping dose steps, and both carry risk. Clinical titration schedules exist because jumping doses before your system has adjusted raises the chance of nausea and other side effects that make continuing the medicine harder, not easier.

Staying in contact with a prescriber who knows your case (rather than starting over elsewhere) is the most clinically sound approach. If you are exploring your weight-loss treatment options or want to understand more about what Mounjaro involves before your next injection, our Mounjaro overview covers the full treatment picture. For anyone new to Mounjaro or considering a switch, speaking to our prescribers is the place to start.